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Immunotherapies and COVID-19 mortality: a 
multidisciplinary open data analysis based on 
FDA’s Adverse Event Reporting System
During the COVID-19 pandemic, the risks and potential bene-
fits of immunotherapies for the treatment of autoimmune 
disorders are still not well defined, and many cohort studies 
neither took the epidemiological dynamics of COVID-19 nor 
the potential capacities of the local healthcare systems in their 
outcome analysis into account. Due to a pronounced heteroge-
neity in the outcome reports of different participating countries, 
the large ‘COVID-19 Global Rheumatology Alliance registry’ 
addressed this issue using a ‘cluster design’ and shed light on 
factors associated with a more severe COVID-19 course in their 
study population.1 We here present data of the US Food and 
Drug Administration (FDA) Adverse Event Reporting System 
(FAERS),2 a postmarketing, self- reporting, open- access phar-
macovigilance platform that contains international data of 
COVID-19 cases. Sources of FAERS are voluntary reports from 
healthcare professionals and consumers. We combine this data 
set with local measurements of the course of the pandemic (from 
Oxford University’s ‘Our World in Data’3) and the potential resil-
iency of the respective healthcare systems (from ‘World Bank’; 
see online supplemental table 1 for full source information). 
Only patients with the diagnosis of an autoimmune disorder 
and a single immunotherapy (required group size: n≥100) at 
the time point of COVID-19 were analysed by multivariable 
regression analysis (online supplemental figure 1), limiting the 
generalisability of our data, for example, concerning combina-
tion therapy scenarios (online supplemental figure 1).
The mean age of patients in our cohort (n=2103) was 51.3 
years (range 3–92 years; SD 14.9), female sex was more preva-
lent (1372/2103, 65.2%) and the majority of cases was reported 
in the USA/Canada (1285/2103, 61.1%). Inflammatory joint 
disease (846/2103, 40.2%), multiple sclerosis (474/2103, 
22.5%) and inflammatory skin disease (435/2103, 20.7%) were 
the most prevalent diagnoses. Anti- tumour necrosis factor α 
(TNFα) therapies were the most frequently used medications for 
the underlying autoimmune disease (714/2103, 34%), followed 
by anti- CD20 therapies (388/2103, 18.4%). Additional cohort 
characteristics are shown in online supplemental table 2 and 
the monthly distribution of cases and cases by country in online 
supplemental figure 2.
In all, 26.3% of the reported patients were hospitalised 
(553/2103), and the overall reported mortality rate in our cohort 
was 5.1% (107/2103; for other outcomes, see online supple-
mental table 3). In the multivariable logistic regression anal-
ysis, age (OR per year 1.1; 95% CI 1.07 to 1.1; p<0.001) and 
female sex (OR 0.6; 95% CI 0.4 to 0.9; p=0.02) were significant 
predictors of mortality. Regarding immunotherapies, patients 
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Figure 1 MLR showing the OR for ‘death’: 95% CIs and p values of the independent variables on a 10- log scale. (A) ORs for age, sex, hospital 
beds per 1000 persons/per country, health expenditure per person/per country (in US$), region and immunotherapy. (B) ORs for each month of 
‘initial FDA received date’. To control for the potential ‘expectation bias’ of FAERS, we included the variable ‘ratio of total reports to FAERS to the 
number of reported deaths to FAERS for each drug in 2018–2020 excluding COVID-19 cases’ (2.8; 0.1 to 84.2; p=0.56; not displayed). As reference 
groups (Region, Immunotherapy, Month), we chose the one with the highest number. Nagelkerke’s R2 is 0.24. For February 2020, no deaths 
have been reported to FAERS; therefore, the OR for February is 0. MLR was conducted with SPSS V.25 (IBM, USA, 2017). For more information 
regarding multivariable analysis adjusted for "month of event" instead of "initial FDA received date" see online supplemental figure 3 and for 
univariable analysis online supplemental figure 4. Not displayed: ‘case fatality rate per month of initial FDA received date/country’ (OR 0.5; 0.0 to 
2479.3; p=0.86), ‘new cases per population per month and country’ (OR 51.5; 0.00 to 3.124E+37; p=0.93) and ‘new deaths per population per 
month and country’ (OR 0; p=0.54). CD-20, Cluster of Differentiation-20; FAERS, US Food and Drug Administration (FDA) Adverse Event Reporting 
System; IL-12/23, interleukin 12/23; IL-17, interleukin 17; JAKinib, Janus kinase inhibitor; MLR, multivariable logistic regression; PDE4- Inhibitor, 
phosphodiesterase-4 inhibitor; S1P- Receptor Modulator, sphingosine-1 phosphate receptor modulator; TNFα, tumour necrosis factor α.
 on N
ovem










is: first published as 10.1136/annrheum




2 Ann Rheum Dis Month 2021 Vol 0 No 0
Letter
under anti- CD20 therapies had an increased mortality (OR 4.5; 
95% CI 2.6 to 7.9; p<0.001), whereas those under anti- IL17 
therapies had a reduced mortality (OR 0.2; 95% CI 0.04 to 0.67; 
p=0.01) compared with anti- TNFα therapies (reference group; 
figure 1).
In summary, using international open data sets and adjusting 
for local infectious diseases dynamics and the potential resil-
ience of the national healthcare systems, our study demon-
strates that anti- CD20 therapies are associated with a higher 
COVID-19 mortality risk in people with autoimmune disorders. 
This finding is in line with other cohort studies.1 4 Regarding the 
potential protective capacities of anti- IL17 treatments, further 
studies are needed. This study also identified age and male sex 
as relevant predictors of COVID-19- associated mortality, which 
should therefore be taken into account in individual risk–benefit 
assessments. Our study has several limitations, for example, the 
fact that FAERS reports basic information on patients. We could 
not analyse disease- specific characteristics, comorbidities and 
risk factors, which have previously shown to influence mortality 
risks, thus representing a limitation of our analysis. Furthermore, 
adjustment for individual disease groups was not possible due to 
multicollinearity to immunotherapies. Biological therapies and 
recently approved oral immunotherapies are over- represented 
compared with classical immunotherapies, pointing towards 
a selection bias of FAERS. Furthermore, we cannot report the 
method of SARS- CoV-2 detection, as this information is not 
included in the FAERS data set.
Finally, we consider the use of combined open- access, phar-
macoepidemiological data and a multidisciplinary approach, 
despite its limitations, as a valuable tool to address the various 
issues posed by the SARS- CoV-2 pandemic. Our findings might 
represent a complement to already published data and call for 
intensified investigations within larger cohort and translational 
studies.
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